PDF(Pubmed)
Abstract：
Hepatitis B virus (HBV) reactivation poses a significant clinical challenge, especially in patients undergoing immunosuppressive therapies, including monoclonal antibody treatments. This manuscript briefly explores the complex relationship between monoclonal antibody therapy and HBV reactivation, drawing upon current literature and clinical case studies. It delves into the mechanisms underlying this phenomenon, highlighting the importance of risk assessment, monitoring, and prophylactic measures for patients at risk. The manuscript aims to enhance the understanding of HBV reactivation in the context of monoclonal antibody therapy, ultimately facilitating informed clinical decision-making and improved patient care. This paper will also briefly review the definition of HBV activation, assess the risks of reactivation, especially in patients treated with monoclonal antibodies, and consider management for patients with regard to screening, prophylaxis, and treatment. A better understanding of patients at risk can help clinicians provide optimum management to ensure successful patient outcomes and prevent morbidity.
摘要：
乙型肝炎病毒（HBV）的再激活提出了重大的临床挑战，尤其是在接受免疫抑制治疗的患者中，包括单克隆抗体治疗。这篇手稿简要探讨了单克隆抗体治疗和HBV再激活之间的复杂关系，借鉴当前文献和临床案例研究。它深入研究了这种现象背后的机制，强调风险评估的重要性，监测,以及对有风险患者的预防措施。该手稿旨在加强在单克隆抗体治疗的背景下，HBV再激活的理解，最终促进知情的临床决策和改善患者护理。本文还将简要回顾HBV激活的定义,评估重新激活的风险，特别是在用单克隆抗体治疗的患者中，并考虑对患者进行筛查管理，预防,和治疗。更好地了解处于危险中的患者可以帮助临床医生提供最佳管理，以确保成功的患者预后并预防发病。
